# PureFDA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/purefda

- Industry: Business Support Services
- Headquarters: Guangzhou, China
- Website: www.purefda.cn
- Total disclosed funding: $14M
- Latest round: Series B (Oct 18, 2022)
- Investors on record: 3

## About

Based in Guangzhou, China, and founded in 2020, PureID Medical Technology Co., Ltd. doing business named PureFDA, is a business support service company that provides compliance services for medical devices accessing to the global market. It has 6 branches in China, including Shanghai, Wuhan, and Hong Kong. PureFDA also has 7 clinical trial centres oversea, and clinical centres in Europe and the United States received CLIA CAP, ISO 17025, and other qualifications. And its services cover 10 countries and regions, including the United States, Germany, Italy, and Poland. 

PureFDA provides compliance services for medical devices, in vitro diagnosis, and medical software artificial intelligence (AI) sold to oversea markets. The compliance services include the US food and drug administration (FDA) 510(k) medical device certification, FDA corporate registration, medical device ISO certification, CE certification, Australian regulatory system, and local medical devices law regulation. It also provides oversea clinical trial services. Meantime, it operates a global regulatory intelligence platform, which allows to access over 100 countries, 600,000 global wholesalers, and 3 million global medical device registration information, adopting big data, and artificial intelligence technologies. Moreover, it launched mini-programs that provide product classification intelligent dialogue robots, and test suggestion intelligent dialogue robots.

## Funding rounds

- Series B, Oct 18, 2022, $14M — Legend Capital, Kangjun Capital
- Series A, Jan 28, 2022 — Kangjun Capital, Probe New Medical Fund

## Investors

- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series A, Series B
- Probe New Medical Fund — Series A
- Legend Capital — Series B